비교리스트

 카트 문의
시장보고서
상품코드
1362999

바이오테크놀러지 기기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 최종 용도별, 부문별 예측(2023-2030년)

Biotechnology Instruments Market Size, Share & Trends Analysis Report By Product (Cell Culture Instruments, Analytical Instruments), By End-use (Pharma & Biotech Companies, Academic & Research Institutes), And Segment Forecasts, 2023 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 180 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

바이오테크놀러지 기기 시장의 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면 세계 바이오테크놀러지 기기 시장 규모는 2030년까지 1,166억 8,000만 달러에 달할 것으로 예상되며, 2023년부터 2030년까지 연평균 3.94%의 CAGR을 보일 것으로 예상됩니다.

생명과학 연구 기술의 발전, 개인 맞춤형 의약품 및 진단 검사에 대한 수요 증가, 암과 같은 질병에 대한 의약품 및 백신 개발 연구 및 개발의 증가로 인해 POC 진단에 대한 수요가 증가하고 있으며, 입원 기간을 단축하기 위한 외래 진료 모델 구축을 위한 정부의 노력 증가, 고령 인구의 재택 의료 환경에서의 POC 기기 수요 증가 등의 요인으로 인해 POC 진단 수요가 증가할 것으로 예상됩니다. 재원일수 단축을 위한 외래 진료 모델 확립을 위한 정부의 노력 증가, 재택 및 의료 환경에서의 POC 장비에 대한 수요 증가 등의 요인이 POC 진단 수요를 견인할 것으로 예상됩니다.

또한, 생명공학 산업의 확장은 신제품 및 혁신 제품 도입, 계약, 인수, 기술 발전, 다양한 응용 분야에서의 채택 확대 등 다양한 요인과 관련이 있습니다. 2023년 5월, 인도의 스타트업 기업인 NeoDx Biotech Labs는 C형 간염, B형 간염, B형 간염, HIV 등의 감염병을 진단하는 실시간 PCR 기반 키트 7종을 출시하여 다양한 병원과 진단센터에서 활용되고 있습니다. 마찬가지로 2023년 1월, Bio-Rad는 FDA의 IVD 검사 승인을 받은 실시간 PCR 시스템 CFX Opus Deepwell Dx의 출시를 발표했습니다. 따라서 이러한 기술적 출시는 해당 기간 동안 시장 성장을 촉진할 것으로 예상됩니다. 또한, 기업들은 더 나은 고급 시퀀싱 기술을 촉진하는 신제품을 출시하고 있습니다.

예를 들어, 2023년 4월 Biomodal(구 Cambridge Epigenetix)은 duet 멀티오믹스 솔루션 출시를 발표했습니다. 이 새로운 멀티오믹스 시퀀싱 기술은 단일 소량 샘플에서 추출한 유전학적 및 에피제네틱스적 인사이트의 시너지 효과를 강조할 것으로 예상됩니다. 또한, 이 솔루션은 단일 샘플에서 유전학적 세부 사항과 에피제네틱스적 세부 사항을 동시에 단계적으로 읽어낼 수 있는 최초의 단일 염기서열 분석 기술 중 하나입니다. 이를 통해 모든 시퀀싱 플랫폼과 통합된 워크플로우에서 이 기술의 적용 범위를 넓힐 수 있습니다. 시퀀싱 기술에서 기술 발전의 채택이 증가함에 따라 시장 성장을 촉진할 것으로 예상됩니다.

바이오테크놀러지 기기 시장 보고서 하이라이트

  • 제품별로는 분석 기기 부문이 2022년 61.92%의 점유율로 시장을 장악했습니다.
  • 첨단 의약품 개발, 바이오마커 탐색, 의약품 품질 관리에 대한 수요 증가는 예측 기간 동안 이 부문의 성장을 촉진할 것으로 예상됩니다.
  • 최종 용도별로는 제약 및 생명공학 기업이 2022년 38.10%로 가장 큰 시장 점유율을 차지했습니다.
  • 이는 암과 같은 다양한 질병에 대한 약물 치료의 증가, 백신 개발, 질병 모니터링 및 검출을 위한 진단 도구의 설계 등에 기인합니다.
  • 2022년에는 북미가 43.95%의 점유율로 시장을 독점했는데, 이는 대기업의 존재와 탄탄한 의료 인프라에 기인합니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 변수, 동향, 범위

  • 시장 계통 전망
  • 시장 동향과 전망
  • 시장 역학
  • 시장 성장 억제요인 분석
  • 사업 환경 분석

제4장 제품 비지니스 분석

  • 바이오테크놀러지 기기 시장 : 제품 변동 분석
  • 분석 기기
    • 중합효소 연쇄 반응
    • 분광법
    • 현미경검사
    • 크로마토그래피
    • 유세포 분석
    • 시퀀싱
    • 마이크로어레이
    • 기타
  • 세포배양 기기
    • 배양 시스템
    • 보육기
    • 극저온 보존 장비
    • 바이오세이프티 장비
    • 피펫 기구
  • 세포 분리 기기
    • 원심
    • 여과 시스템
    • 자기 활성화 세포 분리 시스템
  • 면역측정 기기
  • 임상화학 분석기
  • 기타

제5장 최종 용도 비지니스 분석

  • 바이오테크놀러지 기기 시장 : 최종 용도 변동 분석
  • 제약·바이오테크놀러지 기업
  • 병원·진단 연구소
  • 학술·연구기관
  • 기타

제6장 지역 비지니스 분석

  • 지역 시장 현황
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 스페인
    • 프랑스
    • 이탈리아
    • 덴마크
    • 스웨덴
    • 노르웨이
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 한국
    • 태국
    • 호주
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 쿠웨이트

제7장 경쟁 상황

  • 기업 분류
  • 전략 매핑
  • 기업의 시장 점유율 분석, 2022년
  • 기업 개요·리스트
    • Thermo Fisher Scientific, Inc.
    • Waters Corp.
    • Shimadzu Corp.
    • Danaher
    • Agilent Technologies, Inc.
    • Bruker Corp.
    • PerkinElmer, Inc.
    • Mettler Toledo
    • Zeiss Group
    • Bio-Rad Laboratories, Inc.
    • Illumina, Inc.
    • Eppendorf SE
    • F. Hoffmann-La Roche AG
    • Sartorius AG
    • Avantor, Inc.
ksm 23.11.01

Biotechnology Instruments Market Growth & Trends:

The global biotechnology instruments market size is expected to reach USD 116.68 billion by 2030, according to a new report by Grand View Research, Inc.., exhibiting a CAGR of 3.94% from 2023 to 2030. The growing advancements in life science research technologies, growing demand for personalized medicines & diagnostics tests, and rising R&D for drug & vaccine developments for diseases, such as cancer, collectively propel the market growth. The demand for POC diagnostics is projected to be driven by factors, such as increasing government initiatives to establish outpatient care models for shortening hospital stays and the rising need for POC devices in home & healthcare settings to address the needs of the elderly population.

In addition, the expansion of the biotechnology industry can be linked to various factors including the introduction of new & innovative products, agreements, acquisitions, technological advancements, and growing adoption across different applications. In May 2023, NeoDx Biotech Labs, an Indian startup, launched 7 real-time PCR-based kits to diagnose infectious diseases, such as Hepatitis C, Hepatitis B, and HIV, at various hospitals and diagnostic centers. Similarly, in January 2023, Bio-Rad announced the launch of a real-time PCR system, CFX Opus Deepwell Dx, which is FDA-approved for IVD testing. Thus, these technological launches are projected to impel the market growth over the period. In addition, companies are launching new products to facilitate better and more advanced sequencing technology.

For instance, in April 2023, Biomodal, formerly known as Cambridge Epigenetix, announced the launch of the duet multiomics solution. This new multiomics sequencing technology is projected to highlight the synergistic potential of genetic and epigenetic insights extracted from a single low-volume sample. Moreover, the solution is one of the first single-base-resolution sequencing technologies, which enables simultaneous, phased reading of both genetic and epigenetic details from a single sample. This increases applications of the technology in unified workflows alongside any sequencing platforms. The increasing adoption of technological advancements in sequencing techniques is anticipated to impel market growth.

Biotechnology Instruments Market Report Highlights:

  • Based on product, the analytical instruments segment dominated the market in 2022 with a share of 61.92%
  • The growing demand for advanced drug development, biomarker discovery, and quality control across pharmaceuticals is anticipated to fuel the segment growth over the forecast period
  • Based on end-use, the pharmaceutical & biotechnological companies segment held the largest market share of 38.10% in 2022
  • This can be attributed to the increased number of drug therapies for various diseases, such as cancer, vaccine developments, and designing diagnostic tools for disease monitoring & detection
  • In 2022, North America dominated the market with a share of 43.95% owing to the presence of major players and robust healthcare infrastructure

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product Segment
    • 1.2.2. End-use Segment
  • 1.3. Research Assumptions
  • 1.4. Information Procurement
    • 1.4.1. Primary Research
  • 1.5. Information or Data Analysis
  • 1.6. Market Formulation & Validation
  • 1.7. Market Model
  • 1.8. Global Market: CAGR Calculation
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2
    • 1.9.3. Objective 3

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends And Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Increasing Demand For Analytical Instruments
    • 3.3.2. Growing Prevalence Of Target Diseases And Rising Geriatric Population
    • 3.3.3. Technological Advancements In Research-Use Instruments
  • 3.4. Market Restraint Analysis
    • 3.4.1. Higher Cost Of Devices
    • 3.4.2. Shortage Of Skilled Professionals
  • 3.5. Business Environment Analysis
    • 3.5.1. PESTEL Analysis
    • 3.5.2. Porter's Five Forces Analysis
    • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

  • 4.1. Biotechnology Instruments Market: Product Movement Analysis
  • 4.2. Analytical Instruments
    • 4.2.1. Analytical Instruments Market, 2018 - 2030 (USD Million)
    • 4.2.2. Polymerase Chain Reaction
      • 4.2.2.1. Polymerase Chain Reaction, 2018 - 2030 (USD Million)
    • 4.2.3. Spectroscopy
      • 4.2.3.1. Spectroscopy, 2018 - 2030 (USD Million)
    • 4.2.4. Microscopy
      • 4.2.4.1. Microscopy, 2018 - 2030 (USD Million)
    • 4.2.5. Chromatography
      • 4.2.5.1. Chromatography, 2018 - 2030 (USD Million)
    • 4.2.6. Flow Cytometry
      • 4.2.6.1. Flow Cytometry, 2018 - 2030 (USD Million)
    • 4.2.7. Sequencing
      • 4.2.7.1. Sequencing, 2018 - 2030 (USD Million)
    • 4.2.8. Microarray
      • 4.2.8.1. Microarray, 2018 - 2030 (USD Million)
    • 4.2.9. Others
      • 4.2.9.1. Others, 2018 - 2030 (USD Million)
  • 4.3. Cell Culture Instruments
    • 4.3.1. Cell Culture Instruments Market, 2018 - 2030 (USD Million)
    • 4.3.2. Culture Systems
      • 4.3.2.1. Culture Systems Market, 2018 - 2030 (USD Million)
    • 4.3.3. Incubators
      • 4.3.3.1. Incubators Market, 2018 - 2030 (USD Million)
    • 4.3.4. Cryostorage Equipment
      • 4.3.4.1. Cryostorage Equipment Market, 2018 - 2030 (USD Million)
    • 4.3.5. Biosafety Equipment
      • 4.3.5.1. Biosafety Equipment Market, 2018 - 2030 (USD Million)
    • 4.3.6. Pipetting Instruments
      • 4.3.6.1. Pipetting Instruments Market, 2018 - 2030 (USD Million)
  • 4.4. Cell Separation Instruments
    • 4.4.1. Cell Separation Instruments Market, 2018 - 2030 (USD Million)
    • 4.4.2. Centrifuge
      • 4.4.2.1. Centrifuge Market, 2018 - 2030 (USD Million)
    • 4.4.3. Filtration Systems
      • 4.4.3.1. Filtration Systems Market, 2018 - 2030 (USD Million)
    • 4.4.4. Magnetic-activated Cell Separator Systems
      • 4.4.4.1. Magnetic-activated Cell Separator Systems Market, 2018 - 2030 (USD Million)
  • 4.5. Immunoassay Instruments
    • 4.5.1. Immunoassay Instruments Market, 2018 - 2030 (USD Million)
  • 4.6. Clinical Chemistry Analyzers
    • 4.6.1. Clinical Chemistry Analyzers Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. End-use Business Analysis

  • 5.1. Biotechnology Instruments Market: End-use Movement Analysis
  • 5.2. Pharmaceutical & Biotechnology Companies
    • 5.2.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
  • 5.3. Hospitals & Diagnostic Laboratories
    • 5.3.1. Hospitals & Diagnostics Laboratories Market, 2018 - 2030 (USD Million)
  • 5.4. Academic & Research Institutes
    • 5.4.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Regional Market Snapshot
  • 6.2. North America
    • 6.2.1. North America Biotechnology Instruments Market, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.2.2.2. Key Country Dynamics
      • 6.2.2.3. Competitive Scenario
      • 6.2.2.4. Target Disease Prevalence
      • 6.2.2.5. Regulatory Framework
    • 6.2.3. Canada
      • 6.2.3.1. Canada Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.2.3.2. Key Country Dynamics
      • 6.2.3.3. Competitive Scenario
      • 6.2.3.4. Target Disease Prevalence
      • 6.2.3.5. Regulatory Framework
  • 6.3. Europe
    • 6.3.1. Europe Biotechnology Instruments Market, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. UK Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.3.2.2. Key Country Dynamics
      • 6.3.2.3. Competitive Scenario
      • 6.3.2.4. Target Disease Prevalence
      • 6.3.2.5. Regulatory Framework
    • 6.3.3. Germany
      • 6.3.3.1. Germany Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.3.3.2. Key Country Dynamics
      • 6.3.3.3. Competitive Scenario
      • 6.3.3.4. Target Disease Prevalence
      • 6.3.3.5. Regulatory Framework
    • 6.3.4. Spain
      • 6.3.4.1. Spain Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.3.4.2. Key Country Dynamics
      • 6.3.4.3. Competitive Scenario
      • 6.3.4.4. Target Disease Prevalence
      • 6.3.4.5. Regulatory Framework
    • 6.3.5. France
      • 6.3.5.1. France Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.3.5.2. Key Country Dynamics
      • 6.3.5.3. Competitive Scenario
      • 6.3.5.4. Target Disease Prevalence
      • 6.3.5.5. Regulatory Framework
    • 6.3.6. Italy
      • 6.3.6.1. Italy Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.3.6.2. Key Country Dynamics
      • 6.3.6.3. Competitive Scenario
      • 6.3.6.4. Target Disease Prevalence
      • 6.3.6.5. Regulatory Framework
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.3.7.2. Key Country Dynamics
      • 6.3.7.3. Competitive Scenario
      • 6.3.7.4. Target Disease Prevalence
      • 6.3.7.5. Regulatory Framework
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.3.8.2. Key Country Dynamics
      • 6.3.8.3. Competitive Scenario
      • 6.3.8.4. Target Disease Prevalence
      • 6.3.8.5. Regulatory Framework
    • 6.3.9. Norway
      • 6.3.9.1. Norway Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.3.9.2. Key Country Dynamics
      • 6.3.9.3. Competitive Scenario
      • 6.3.9.4. Target Disease Prevalence
      • 6.3.9.5. Regulatory Framework
  • 6.4. Asia Pacific
    • 6.4.1. Asia-Pacific Biotechnology Instruments Market, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Japan Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.4.2.2. Key Country Dynamics
      • 6.4.2.3. Competitive Scenario
      • 6.4.2.4. Target Disease Prevalence
      • 6.4.2.5. Regulatory Framework
    • 6.4.3. China
      • 6.4.3.1. China Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.4.3.2. Key Country Dynamics
      • 6.4.3.3. Competitive Scenario
      • 6.4.3.4. Target Disease Prevalence
      • 6.4.3.5. Regulatory Framework
    • 6.4.4. India
      • 6.4.4.1. India Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.4.4.2. Key Country Dynamics
      • 6.4.4.3. Competitive Scenario
      • 6.4.4.4. Target Disease Prevalence
      • 6.4.4.5. Regulatory Framework
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.4.5.2. Key Country Dynamics
      • 6.4.5.3. Competitive Scenario
      • 6.4.5.4. Target Disease Prevalence
      • 6.4.5.5. Regulatory Framework
    • 6.4.6. Thailand
      • 6.4.6.1. Thailand Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.4.6.2. Key Country Dynamics
      • 6.4.6.3. Competitive Scenario
      • 6.4.6.4. Target Disease Prevalence
      • 6.4.6.5. Regulatory Framework
    • 6.4.7. Australia
      • 6.4.7.1. Australia Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.4.7.2. Key Country Dynamics
      • 6.4.7.3. Competitive Scenario
      • 6.4.7.4. Target Disease Prevalence
      • 6.4.7.5. Regulatory Framework
  • 6.5. Latin America
    • 6.5.1. Latin America Biotechnology Instruments Market, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.5.2.2. Key Country Dynamics
      • 6.5.2.3. Competitive Scenario
      • 6.5.2.4. Target Disease Prevalence
      • 6.5.2.5. Regulatory Framework
    • 6.5.3. Mexico
      • 6.5.3.1. Mexico Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.5.3.2. Key Country Dynamics
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. Target Disease Prevalence
      • 6.5.3.5. Regulatory Framework
    • 6.5.4. Argentina
      • 6.5.4.1. Argentina Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.5.4.2. Key Country Dynamics
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Target Disease Prevalence
      • 6.5.4.5. Regulatory Framework
  • 6.6. MEA
    • 6.6.1. MEA Biotechnology Instruments Market, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. South Africa Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.6.2.2. Key Country Dynamics
      • 6.6.2.3. Competitive Scenario
      • 6.6.2.4. Target Disease Prevalence
      • 6.6.2.5. Regulatory Framework
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Saudi Arabia Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.6.3.2. Key Country Dynamics
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. Target Disease Prevalence
      • 6.6.3.5. Regulatory Framework
    • 6.6.4. UAE
      • 6.6.4.1. UAE Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.6.4.2. Key Country Dynamics
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. Target Disease Prevalence
      • 6.6.4.5. Regulatory Framework
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Biotechnology Instruments Market, 2018 - 2030 (USD Million)
      • 6.6.5.2. Key Country Dynamics
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Target Disease Prevalence
      • 6.6.5.5. Regulatory Framework

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Share Analysis, 2022
  • 7.4. Company Profiles/Listing
    • 7.4.1. Thermo Fisher Scientific, Inc.
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Waters Corp.
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Shimadzu Corp.
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Danaher
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Agilent Technologies, Inc.
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Bruker Corp.
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. PerkinElmer, Inc.
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Mettler Toledo
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Zeiss Group
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Bio-Rad Laboratories, Inc.
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives
    • 7.4.11. Illumina, Inc.
      • 7.4.11.1. Company Overview
      • 7.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Strategic Initiatives
    • 7.4.12. Eppendorf SE
      • 7.4.12.1. Company Overview
      • 7.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.12.3. Product Benchmarking
      • 7.4.12.4. Strategic Initiatives
    • 7.4.13. F. Hoffmann-La Roche AG
      • 7.4.13.1. Company Overview
      • 7.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.13.3. Product Benchmarking
      • 7.4.13.4. Strategic Initiatives
    • 7.4.14. Sartorius AG
      • 7.4.14.1. Company Overview
      • 7.4.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.14.3. Product Benchmarking
      • 7.4.14.4. Strategic Initiatives
    • 7.4.15. Avantor, Inc.
      • 7.4.15.1. Company Overview
      • 7.4.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.15.3. Product Benchmarking
      • 7.4.15.4. Strategic Initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제